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Abstract
Background: To demonstrate the use of risk-benefit analysis for comparing multiple competing interventions in
the absence of randomized trials, we applied this approach to the evaluation of five anticoagulants to prevent
thrombosis in patients undergoing orthopedic surgery.
Methods: Using a cost-effectiveness approach from a clinical perspective (i.e. risk benefit analysis) we compared
thromboprophylaxis with warfarin, low molecular weight heparin, unfractionated heparin, fondaparinux or
ximelagatran in patients undergoing major orthopedic surgery, with sub-analyses according to surgery type.
Proportions and variances of events defining risk (major bleeding) and benefit (thrombosis averted) were obtained
through a meta-analysis and used to define beta distributions. Monte Carlo simulations were conducted and used
to calculate incremental risks, benefits, and risk-benefit ratios. Finally, net clinical benefit was calculated for all
replications across a range of risk-benefit acceptability thresholds, with a reference range obtained by estimating
the case fatality rate - ratio of thrombosis to bleeding.
Results: The analysis showed that compared to placebo ximelagatran was superior to other options but final
results were influenced by type of surgery, since ximelagatran was superior in total knee replacement but not in
total hip replacement.
Conclusions: Using simulation and economic techniques we demonstrate a method that allows comparing
multiple competing interventions in the absence of randomized trials with multiple arms by determining the
option with the best risk-benefit profile. It can be helpful in clinical decision making since it incorporates risk,
benefit, and personal risk acceptance.
Keywords: Risk-Benefit Analysis, Decision Making, Meta-Analysis, Methods, Monte Carlo Method, Risk, indirect
comparison
Background
In daily clinical practice clinicians are frequently pre-
sented with multiple competing treatment alternatives
for the same clinical situation. In general it is accepted
that when comparing several therapeutic alternatives the
best evidence is derived from randomized trials. How-
ever, randomized trials are usually conducted comparing
only two (or seldom three) options because inclusion of
more treatment groups would require prohibitively large
sample sizes and substantial increases in research costs
and as a consequence, studies comparing all available
treatment options at the same time are usually lacking.
Some notions should be noted regarding clinical deci-
sions. First, if two or more equally effective alternatives
are available for a disease the preferred one should be
that conveying the lesser risk. Conversely, if all alterna-
tives have equal risk, clinicians should opt for the most
beneficial. Second, an alternative is usually not chosen if
the risk associated with it outweighs the expected bene-
fit [1]. The decision of using a specific option ultimately
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sion maker’s perception of the associated benefits and
risks with the potential caveat that such perception
depends on factors such as the clinician’se x p e r i e n c e ,
knowledge, and expertise. Furthermore, when multiple
alternatives exist for the same situation, the risks and
benefits associated with each alternative should be pon-
dered before deciding for a particular option.
Risks and benefits from medical interventions should
be assessed together because their occurrence is inter-
related and ideally, several factors should be considered
in the decision process including: the expected clinical
benefits and risks for each alternative, the uncertainty of
these parameters, and the clinician’s personal preference
regarding the trade-off between benefits and risks [1,2].
A problem with this framework is that simultaneously
incorporating all of the aforementioned factors for each
available option in the decision process while at the
same time considering all available evidence is practi-
cally difficult and not straightforward. Furthermore,
since there are variations in personal preference for the
trade-off between risks and benefits, comparative risk-
benefit summaries should be presented throughout a
range of trade-off values.
There has been an increasing interest in methods for
jointly assessing risk and benefit and some work has
been done in this area [3-7]. Proposed approaches to
evaluate benefit and risk i n c l u d eu s i n gt h en u m b e r
needed to treat and the number needed to harm [4,5,8].
These estimations are generally used independently and
they are seldom combined in a risk-benefit ratio. Major
problems with this approach are: a) the risk-benefit ratio
is difficult to interpret and extrapolate outside the trial
generating the information, and b) assessing uncertainty
of a ratio is difficult because estimation of confidence
intervals is problematic [9-11]. Additionally, besides
being conceptually difficult to interpret, these
approaches have the disadvantage of not allowing a
comparison between multiple agents when these are
available for the same indication. Methods using meta-
analytical techniques have been developed to indirectly
compare interventions that have not been directly com-
pared; however, these methods involve a comparison of
effect sizes (e.g. odds ratios) and result in estimates with
wide confidence intervals which are difficult to interpret
and do not provide a conjoint assessment of benefits
and risks [12,13]. A possible way to solve some of the
aforementioned problems that takes advantage of the
Bayesian framework is the use of modeling techniques
that allow introducing a term of uncertainty around a
parameter estimate using strategies such as Monte Carlo
simulation or non-parametric bootstrapping [11,14-16].
In 2004 Lynd and O’B r i e np r o p o s e da ni n t e r e s t i n g
approach to this problem [2]. Their method used a cost-
effectiveness approach similar to the one used in the
health economics literature [17] and involves the estima-
tion of the joint density of incremental risk and incre-
mental benefit using probabilistic simulation, which is
then plotted in a risk-benefit plane analogous to the
cost-benefit plane used in economics (Figure 1)[18];
then a risk-benefit acceptability curve (RBAC) is created.
This curve shows the proportion of net risk-beneficial
interventions at a given threshold for risk acceptance
and is analogous to the cost-effectiveness acceptability
curve [19]. A limitation of this method is that each
curve compares only two interventions and, although
multiple curves can be superimposed in a single plot,
this will only inform the probability for each interven-
tion of being risk-beneficial but it would not allow
determining which one has the best risk-benefit profile.
Herein we elaborate on an extension of the method
proposed by Lynd and O’Brien [2] in order to compare
multiple competing interventions. We use information
obtained from a meta-analysis of the literature to esti-
mate the clinical risk (i.e. the “clinical cost”) and benefit
of each intervention together with an estimation of their
corresponding uncertainties and, given that the optimal
cutoff value for the tradeoff between risks and benefits
is usually not known, we present the information
through a range of tradeoff values which allows
Figure 1 Risk-benefit plane showing a hypothetical conjoint
risk-benefit analysis. In this hypothetical example, each point
represents a joint risk-benefit observation calculated from a
replication obtained from the Monte Carlo simulation. The
percentage of the observations lying below the risk-benefit
acceptability threshold (solid line) represents the probability of the
intervention being net-beneficial for that specific threshold. It can
be noted that a higher value of the threshold (i.e. a higher risk
acceptance) will result in a higher probability of the intervention
being net risk-beneficial.
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Finally, we incorporate a reference tradeoff value based
on the clinical relevance of risk and benefit.
Methods
It is well known that major orthopedic surgery, includ-
ing total knee or hip arthroplasty, is associated with an
increased risk of venous thromboembolic disease (VTE)
-comprising deep vein thrombosis and pulmonary
embolism- that might be as high as 85% and that antic-
oagulants decrease this risk but also result in increased
bleeding events [20]. Given the high case-fatality rate of
major bleeding avoiding an excess bleeding risk is as
important as achieving a good preventive effect. In addi-
tion, anticoagulants have very few side effects other than
hemorrhage and thus their risk and benefit can be read-
ily defined. Several anticoagulant drugs are available for
this indication but they all differ in their efficacy and
safety and therefore, in order to define the best inter-
vention the ideal study should include 5 or 6 arms mak-
ing it unfeasible. We used a risk-benefit analysis
framework as outlined in the following sections to com-
pare five different anticoagulants for the prevention of
VTE in patients undergoing major orthopedic surgery.
Estimation of risks and benefits
While measuring the clinical benefit derived from an
intervention is usually straightforward, defining the risk
can be more problematic. Risk should be defined by an
intervention-derived adverse event. Ideally, the interven-
tion should have only one or very few adverse effects, of
which the most frequent should be used to define the
clinical cost. Alternatively, a composite endpoint can be
used to incorporate different adverse events into a single
outcome measure (e.g. mortality due to all causes or
permanent disability). Since the risk and the benefit are
defined by clinical events, it is necessary to know the
proportion of patients experiencing such events. This
can be obtained from a systematic review and meta-ana-
lysis of published evidence, which if properly conducted
should provide a relatively unbiased summary of the
available information [21].
To demonstrate the use of the methods proposed
herein we use data from a previously conducted meta-
analysis evaluating the use of anticoagulants for prophy-
laxis of VTE in patients undergoing major orthopedic
surgery [22]. We included randomized controlled trials
evaluating short-term (< 15 days) administration of
anticoagulants for VTE prophylaxis in patients under-
going total hip or knee arthroplasty. The main benefit
outcome was the proportion of major VTE (proximal
deep vein thrombosis, pulmonary embolism or death)
assessed by previously validated criteria [23]. The risk
was assessed by estimating the proportion of major
bleeding using a standard definition [24]. The search
included MEDLINE, EMBASE, The Cochrane Library
and also grey literature and was included studies pub-
lished between 1980 and 2005. Details on the search
strategy are available from the authors upon request.
The retrieved references were evaluated for inclusion
independently by 2 reviewers and discrepancies were
resolved by consensus. Data was abstracted by one
reviewer and independently verified by a second reviewer.
Quality of the studies was assessed using the criteria pro-
posed by Jadad [25] and allocation concealment was eval-
uated according to the definition proposed by Schulz and
Grimes [26]. A meta-analysis of proportions was con-
ducted to obtain pooled estimates of proportions and
their variances using a fixed or random effects model as
described in Appendix 1. To determine the appropriate
statistical model to be used, heterogeneity of the propor-
tions across individual studies was calculated using a c
2
statistic for a k × 2 table, considering as statistically sig-
nificant a p < 0.1. Individual subgroup and sensitivity
analyses were planned ap r i o r ifor type of surgery, ade-
quacy of allocation concealment, source of funding, qual-
ity score, blinded outcome adjudication, timing of
initiation of anticoagulation and type of analysis. Publica-
tion bias was explored plotting point estimates versus
precision, or alternatively sample size. All the analyses
were done using Excel XP version (Microsoft Corp., Red-
mond WA) with the statistical add-in software package
Analyse-it release 1.7 (Analyse-it Software, Leeds UK).
Estimation of uncertainty, joint risk-benefit and risk-
benefit analysis
To determine the risk-benefit profile of a therapeutic
option it is necessary to determine the difference in the
risk (i.e. the incremental risk or ΔR), the difference in
the benefit (i.e. the incremental benefit or ΔB), and the
ratio of both (i.e. the incremental risk-benefit ratio or
IRBR) that such option has compared to a reference,
usually placebo or the standard of treatment. The IRBR
is analogous to the incremental cost-effectiveness ratio
(ICER) and it can be defined as ΔR/ΔB (i.e. the ratio of
the difference in risk to the difference in benefit
between two competing treatments) representing a joint
risk-benefit measure which can be plotted in a risk-ben-
efit plane (Figure 1). An intervention will be dominant if
it provides more benefit with less risk, and it will be
dominated if it provides less benefit with more risk. Pro-
blem arises when interventions provide an increase in
benefit with an associated increase in risk. In such cases
t h ec h o i c ew i l ld e p e n do nt h ed e c i s i o nm a k e r ’s willing-
ness-to-accept the risk. This is called the risk-benefit
acceptability threshold (RBAT) and is represented by
the slope of a line crossing the origin of the risk-benefit
plane (Figure 1).
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the uncertainty around the joint distribution. Uncer-
tainty should be presented to avoid the ambiguity sup-
posed by the use of the ratio alone [11]. Under the
Bayesian framework proposed by Lynd and O’Brien, ΔR
and ΔB are treated as random variables whose values lie
over a specific distribution function, [2]. Since probabil-
ities are limited by 0 and 1, their distribution is better
expressed using the beta distribution which is defined
on the interval (0, 1) and is frequently used as a prior
distribution in Bayesian analysis. It is a continuous prob-
ability distribution with the probability density function
defined by parameters a and b,w h e r ea is the expected
number of subjects that will experience an event and b
is the expected number of subjects that will not experi-
ence an event. In the case of Lynd and O’Brien, they
used data from a single study to conduct further analy-
sis, thus limiting the number of interventions evaluated
to those included in the study used to obtain the infor-
mation. However, the model can also be parameterized
using the information derived from a systematic review
and meta-analysis of the literature to estimate the prob-
ability of a patient experiencing an event, with the
advantage of providing a more pragmatic estimate if the
meta-analysis is well conducted.
We conducted risk-benefit analyses for each competing
anticoagulant. Analyses were conducted from a clinical
perspective and the analytic horizon was short since stu-
dies explored the occurrence of the clinical outcomes
(VTE and bleeding) within 30 days of surgery, and there-
fore no discounting was considered. Using the method of
moments [27] we calculated the a and b parameters of a
beta distribution using the information obtained from
the meta-analysis. Then the a and b values were used to
parameterize a second order Monte Carlo simulation
with 1,000 replications, each one representing a repeat
estimation of the pooled proportion from the distribution
previously defined. The simulations were done using
Microsoft Excel 2002 (Microsoft Corp., Seattle WA) and
CrystalBall 7·1 (Decisioneering Inc. Denver CO) software.
Using the results of the Monte Carlo simulation, we cal-
culated the percentage of the replications lying below a
range of values for the RBAT. These values can be
plotted in a risk-benefit acceptability curve, representing
the probability of the intervention being risk-beneficial
for a range of RBAT values. Although curves can be
superimposed, they will only show the probability of each
intervention being risk beneficial but will not inform
which has the best risk-benefit profile.
Calculation of the net clinical benefit and indirect
comparison of multiple treatment options
Unfortunately, the mathematical properties of the IRBR
yield some limitations: when the difference in effectiveness
(or benefit) is small the confidence bounds may become
too wide which makes it difficult to estimate the uncer-
tainty of the ratio [28]. In economic analyses the use of
the net monetary benefit has been proposed as an alterna-
tive to overcome the problems with the ICER [28]. Using a
similar approach we calculated the net clinical benefit
(NCB) which is analogous to the net monetary benefit and
is a way to assign a clinical value to the increment in clini-
cal benefit that is obtained from the new treatment, sub-
tracting from this the increment in the risk derived from
such treatment. If the NCB is positive it means that the
risk of achieving an additional benefit is less than the
value of the benefit achieved. If the NCB is negative then
the treatment should not be accepted since the risk
exceeds the value of the benefit achieved [29].
Using the probabilistic framework proposed by Lynd
and O’Brien [2], we assumed that a treatment would be
risk-beneficial if the IRBR is less than the RBAT repre-
sented by the linear expression
 R/ B <ρ (1)
where ΔR denotes the differential risk, ΔB the differ-
ential benefit, and r is the RBAT. The inequality can be
re-arranged as
ρ B −  R > 0 (2)
or alternatively
NCB = ρ B −  R (3)
with variance equal to
var (NCB) = ρ2 × var ( B) +v a r ( R) − 2 × cov ( B, R) (4)
where NCB represents the net clinical benefit and for
NCB to be positive rΔB has to be greater than ΔR.
Taking advantage of this approach we extended Lynd
and O’Brien’s [2] method in order to compare multiple
agents by evaluating which anticoagulant(s) result(s) in a
greater clinical benefit when the risk associated with the
intervention has been accounted for.
Using this approach we used data from the Monte
Carlo simulations to calculate the NCBj for each j indi-
vidual simulation trial using the equation
NCBj = ρ Bj −  Rj (5)
where ΔRj is the incremental risk and ΔBj is the incre-
mental benefit obtained in the j individual simulation
trial. The variance can be used to estimate 95 percent
confidence limits if we assume a normal distribution of
the data, or alternatively in order to avoid an assump-
tion of normality we can estimate these limits using the
values for the 2.5 and 97.5 percentiles of the values
obtained from the simulation.
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across a range of r values for each of the five anticoagu-
lant agents included in the systematic review and for
placebo. For each trial and each value of r we deter-
mined which anticoagulant had the highest NCBj.W e
then calculated for each agent and value of r the pro-
portion of trials in which such agent had the highest
NCBj. This proportion represents the probability that
each anticoagulant had of achieving the highest net clin-
ical benefit across a range of rvalues. The results were
then plotted in a net clinical benefit probability curve
which shows which of the competing treatment alterna-
tives is/are most likely to have the best risk-benefit pro-
file at a given RBAT value.
Determination of a reference RBAT
Since the ideal RBAT is usually not known this analytic
approach allows incorporating clinicians’ personal risk
acceptance in the decision process. However, the opti-
mal RBAT depends on the relative weigh of the risk ver-
sus the benefit. However, determining the weighs can be
problematic particularly if the outcomes of risk and ben-
efit are surrogate markers. In the latter case, determin-
ing an outcome common to both risk- and benefit-
defining events is necessary. In this work we obtained
pooled estimates of the case fatality rates for both VTE
and major bleeding and their 95% confidence intervals
using the approach shown in appendix I. Finally, we cal-
culated the case fatality rate ratio of VTE versus bleed-
ing. These ratio indicates the relative importance of
VTE to bleeding, in other words it informs how lethal is
at h r o m b o t i ce v e n tc o m p a r e dt oab l e e d i n ge v e n t .T o
obtain the 95% CI for each ratio, a Monte Carlo simula-
tion was conducted using 1,000 replications of the case
fatality rates and ratios were calculated for each replica-
tion and the 2.5
th and 97.5
th percentile values of the
replications were used to define the 95% confidence
interval.
Results
Systematic review, estimation of risks, benefits, and case
fatality rates
The search of the literature identified 1,583 potentially
relevant citations of which 203 were fully assessed and
55 were included in the final review. These references
are included in additional file 1. The reasons for exclu-
sion and a flow diagram of the review are shown in the
supplementary figure S1 included in additional file 1.
The characteristics of the 55 included studies are shown
in supplementary tables S1 and S2 included in addi-
tional file 1. We included studies evaluating, low mole-
cular weight heparin (LMWH), unfractionated heparin
(UFH), warfarin, fondaparinux, and ximelagatran, and
placebo. The included studies comprised 123
intervention arms 2 of which were excluded. One study
included a danaparoid arm in addition to the tinzaparin
and dalteparin arms; the other study included an indo-
methacin arm together with a nadroparin and a placebo
arms. In total 121 patient groups enrolling 42,131
patients were included in the review. Of these, 24,630
underwent total hip replacement, 13,318 underwent
total knee replacement, 2,001 underwent surgery for hip
fracture, and in 2,182 the type of surgery was not speci-
fied. Of the total number of patients enrolled in all the
studies, 34,209 (81.2%) were evaluable for major VTE
and 40,975 (97.3%) for major bleeding. The methodolo-
gical characteristics of the studies are shown in the sup-
plementary table S2 included in additional file 1. In
general the methodological quality of the reports was
acceptable. Allocation concealment was appropriate in
approximately two thirds of the studies. The majority of
the studies were funded by the pharmaceutical industry,
and most of them used a blinded process to adjudicate
outcomes. Only about one half of the studies used a
similar definition for major bleeding events.
The pooled estimates of VTE and bleeding for all stu-
dies are shown in table 1. The pooled estimates were
obtained using a random effects model. The drugs
resulting in the highest and lowest proportion of major
VTE were UFH and fondaparinux, respectively whereas
those resulting in the highest and lowest proportion of
bleeding were fondaparinux and warfarin, respectively.
Sensitivity analyses showed that only the type of surgery
influenced the occurrence of outcomes and therefore 2
separate analyses for patients undergoing total hip and
total knee replacement were conducted. The random
effects pooled estimates of the proportion of fatal events
(case fatality rates) of major VTE and major bleeding
were 1.391% (95% CI 0.892, 2.162) and 3.557% (95% CI
3.203, 3.911), respectively. Finally, the case fatality rate-
ratio of major VTE with respect to major bleeding was
0.391 (95% CI 0.158, 1.579). In other words, in these
s t u d i e so na v e r a g e ,am a j o rV T Ew a sl e s sl e t h a lt h a na
major bleeding event.
Estimation of uncertainty and risk-benefit analysis
The information on risks and benefits obtained from the
systematic review was used to parameterize Monte
Carlo simulations. The results of the simulations were
used to calculate the incremental benefits and risks for
all anticoagulants which were subsequently used to con-
struct risk-benefit planes. (Figures 2A-E). The propor-
tion of paired observations lying below the risk-benefit
acceptability threshold -represented by a dashed line in
Figure 2- was calculated across a range of values and
plotted in risk-benefit acceptability curves for each
agent that were overlapped in a single plot (Figure 3A).
Separate analyses were conducted for patients
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and 3C). These curves represent the probability that an
agent has of being net-beneficial relative to placebo
across a range of values for the risk-benefit acceptability
threshold. In all analyses, as expected all options had
high probabilities of being net-beneficial compared to
placebo (Proportion > 0.8 with an RBAT = 0.391). The
probabilities did not differ in subgroup analyses accord-
ing to surgery type (total hip or knee replacement).
However, as can be seen in Figure 3, the risk-benefit
acceptability curves do not allow a comparison of all
options at the same time. Thus, in order to compare all
agents we calculated the NCB for each one of the 1000
simulations and subsequently we calculated for each
agent the proportion of the simulated trials in which
each agent had the highest NCB across a range of
RBAT values. Results were plotted as probabilities in
net clinical benefit probability curves (Figures 4A-C).
These curves show which drug(s) has(have) the highest
probability of having the highest net clinical benefit (and
this the best risk-benefit profile) at a given value of the
RBAT. As depicted in Figure 4A, ximelagatran was the
agent with the highest probability (87.8%) of having the
best net-clinical benefit when considering all patients,
b u ts u b g r o u pa n a l y s e ss h o w e dt h a tt h i sd i f f e r e n c ew a s
mainly driven by the total knee replacement population
(Figure 4C) in which the probability was 85.2% for
ximelagatran, and that in the case of total hip replace-
ment patients, the choice between warfarin or ximelaga-
tran would be probably indifferent with probabilities of
obtaining the highest net clinical benefit of 48.6% and
36.7%, respectively. It can be seen that the agents vary
in their probability of having the best risk-benefit profile
as the value of risk acceptance (RBAT) changes. Finally,
because the optimal RBAT is not known, a reference
value was calculated based on ‘hard’ outcomes. The clin-
ical relevance of VTE relative to that of major bleeding
was estimated using the values of the case fatality rate-
ratios. These ratios and their 95% CI were then plotted
in the curves to provide an estimate of the approximate
level of risk acceptance (RBAT) that should be consid-
ered. The ratios were indicated in the curves as the ver-
tical dashed line with the 95% CI indicated by the
shaded area.
Discussion
The present study demonstrates the use of risk-benefit
analysis to perform indirect comparisons of multiple
Table 1 Pooled estimates of proportions for risk and benefit outcomes in studies evaluating the use of anticoagulant
prophylaxis for venous thromboembolism in orthopedic surgery
Drug Major Venous Thromboembolism Major Bleeding
% (95% CI) Variance % (95% CI) Variance
All patients
Ximelagatran 3.274 (3.175, 3.372) 0.098 1.804 (1.722, 1.885) 0.082
LMWH 6.528 (6.357, 6.699) 0.171 2.208 (2.156, 2.260) 0.052
UFH 13.394 (12.862, 13.926) 0.532 2.494 (2.363, 2.625) 0.131
Warfarin 6.278 (6.092, 6.463) 0.186 1.778 (1.690, 1.867) 0.088
Fondaparinux 2.051 (1.957, 2.146) 0.094 5.113 (4.690, 5.536) 0.423
Placebo 21.019 (19.978, 22.060) 1.041 1.781 (1.651, 1.912) 0.130
Total hip replacement
Ximelagatran 3.401 (3.181, 3.621) 0.220 2.892 (2.683, 3.101) 0.209
LMWH 6.472 (6.293, 6.651) 0.179 2.151 (2.085, 2.216) 0.066
UFH 15.154 (14.446, 15.862) 0.708 2.813 (2.625, 3.001) 0.188
Warfarin 4.280 (4.083, 4.477) 0.197 2.229 (2.088, 2.371) 0.141
Fondaparinux 2.138 (2.009, 2.267) 0.129 6.033 (5.501, 6.566) 0.532
Placebo 24.726 (23.268, 26.184) 1.458 1.463 (1.299, 1.628) 0.164
Total knee replacement
Ximelagatran 3.100 (3.042, 3.158) 0.058 1.127 (1.095, 1.159) 0.032
LMWH 5.143 (5.010, 5.277) 0.134 1.605 (1.566, 1.644) 0.039
UFH 9.119 (8.803, 9.436) 0.316 0.943 (0.837, 1.050) 0.106
Warfarin 8.100 (7.879, 8.322) 0.221 0.822 (0.792, 0.852) 0.030
Fondaparinux 2.446 (2.288, 2.603) 0.158 2.128 (2.003, 2.252) 0.124
Placebo 14.833 (14.351, 15.314) 0.482 2.116 (1.911, 2.322) 0.205
VTE Venous thromboembolism; CI Confidence interval; LMWH Low molecular weight heparin; UFH Unfractionated heparin.
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Page 6 of 13competing interventions. We believe that this approach
might help to guide clinical decisions in areas where
tension between risk and benefit exist and there are
multiple therapeutic options. This approach provides a
way to indirectly compare several interventions in the
absence of randomized trials involving multiple arms.
This method assumes that the use of certain therapy
has a clinical risk, something particularly important
when potentially harmful therapies are used. Clinicians
opt for these options because the expected benefit out-
weighs the risk; however, choosing the best therapeutic
option can be difficult when the rates of major
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Figure 2 Risk-benefit planes showing the joint incremental risk and benefit of anticoagulants used for venous thromboembolism
prophylaxis in orthopedic surgery. The figure shows separate analyses for patients receiving ximelagatran (A), low molecular weight heparin
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Figure 3 Risk-benefit acceptability curves for anticoagulants used for venous thromboembolism prophylaxis in orthopedic surgery
compared to placebo for all patients (A), total hip replacement patients (B) and total knee replacement patients (C). The curves show
for each anticoagulant the probability of being net risk-beneficial compared to placebo across different risk-benefit acceptability thresholds
which reflect the willingness to accept the risk of major bleeding episodes. The reference value is shown as the vertical dashed line with the
95% confidence interval shown as the shadowed area. Note that these curves do not allow a comparison of all agents simultaneously and do
not inform the option with the best risk-benefit profile.
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from different options vary. Furthermore, clinicians’
willingness-to-accept the risks might differ depending
on a number of issues. If for a clinical situation there
are numerous therapeutic options it is unlikely that all
options will be compared in a randomized trial usually
because of sample size and research cost constraints.
The approach described herein takes advantage of the
risk-benefit analysis framework and provides a way to
indirectly compare several interventions in order to
determine the one with the best risk-benefit profile
using information available from randomized trials to
estimate costs and benefits.
Using the proposed approach we conducted an indir-
ect comparison of five common anticoagulant drugs
used to prevent the development of thrombotic compli-
cations in patients undergoing major orthopedic surgery.
This intervention is particularly suited to exemplify this
approach given that anticoagulants are associated with
bleeding episodes as their major (and almost only) com-
plication and with a palpable benefit, namely prevention
of thrombosis. Furthermore, they are usually given for a
short period of time which facilitates defining the time
horizon for the study. The analysis showed that com-
pared to placebo, all agents are likely risk-beneficial
(Figures 3A-C), a finding that is not surprising. The pro-
blem is then choosing the one(s) with the best risk-ben-
efit profile. By calculating the net clinical benefit for
each anticoagulant at a particular value of the RBAT it
can be easily determined the probability of obtaining the
highest net clinical benefit for each competing anticoa-
gulant at that particular RBAT value. These probabilities
are then calculated for a range of RBAT values and used
to create a net clinical benefit probability curve (Figures
4A-C). Furthermore, since the ultimate clinical conse-
quences of major bleeding and venous thromboembolic
events might be different (i.e. their associated mortality),
we incorporated in the analysis a reference range of
RBAT values derived from the case fatality rate-ratios of
thrombosis and bleeding. The final plots then incorpo-
rate the key elements of a decision, namely risk, benefit,
willingness to accept the risk and their uncertainties.
It can be argued that when analyzing and pooling
information obtained from randomized trials, the use of
proportions for comparison purposes -as opposed to
effect sizes- supposes the loss of the randomization
effect because groups are treated independently. Never-
theless, if properly conducted and reported, information
d e r i v e df r o mr a n d o m i z e dt r i a l sh a su s u a l l yah i g hq u a l -
ity [30], and although we recognize that there might be
a concern regarding the generalizability of the results
from randomized trials, pooled estimates of event pro-
portions will most likely approach reality as the popula-
tion in the included studies increases. Although non-
randomized studies could potentially also be used we
prefer randomized trials which are less prone to bias.
However, since a number of issues could influence
meta-analysis results, systematic reviews should be
methodologically sound and incorporate a priori all per-
tinent subgroup and sensitivity analyses, an evaluation
of the homogeneity of outcomes’ definitions used across
different studies, and an assessment of study quality
using validated scales [25,31]. This issue can be better
appreciated in our study by analyzing the results for all
patients and the subgroup analyses which showed that
the risk-benefit profiles of the different anticoagulants
were different in patients undergoing hip or knee
replacement
Some conditions are necessary to conduct study using
the approach proposed herein: First, outcomes used to
measure risks and benefits must be defined similarly
across studies. Incorporating studies using different out-
come definitions would result in a heterogeneous result
difficult to interpret. It is entirely possible that the
results of the study example could be different if all and
each one of the potential side effects of the drugs were
incorporated in the analysis. Second, if clinically accep-
table, risks and benefits should ideally be defined by a
single outcome; if this is not possible then a composite
outcome could be used, such as mortality. Third, events
defining risks and benefits should be clinically relevant.
Fourth, if the systematic review spans several years, it is
particularly important to test for secular trends since
outcome definitions might ch a n g eo v e rt i m ea sar e s u l t
of new knowledge, which might affect the evaluation of
older therapies still in use. In addition, changes in medi-
cal or surgical techniques or in health policy are likely
to influence the results and therefore populations might
not be similar. It can be appreciated that the systematic
review must be stringently rigorous and adhere to stan-
dardized requirements such as the PRISMA (formerly
QUOROM) statement and exploring heterogeneity
becomes essential. A thorough sensitivity analysis should
be conducted prior to incorporating the information
into the Monte Carlo simulation, to assure to the maxi-
mum extent that studies include comparable popula-
tions. If these conditions are met, it can be argued that
this approach provides a pragmatic panorama of the
situation studied.
Our approach does not estimate effect sizes; instead it
provides the clinician with information regarding the
probability of having the best risk-benefit profile that
certain intervention will have at a given value of risk
acceptance. If risks and benefits can be measured in
equivalent terms (e.g. deaths induced or prevented by
the treatment), the preferred choice should be that con-
ferring the highest probability of being beneficial at the
chosen value for risk acceptance. However, if surrogate
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and so will be the clinical relevance of costs and benefits
relative to one another. Our method allows for an
adjustment by changing the value of the RBAT to one
that better suits the clinical situation being studied.
Since the level of risk acceptance is pivotal to making
the best choice, a reference value for the RBAT can be
obtained from expert consensus or surveys, or by using
case-fatality rate ratios. In any case a reference RBAT
should be a guideline for the clinician to be applied on
an individual basis.
It is important to note that randomized trials are
usually powered to detect differences in benefit-defining
events and inadequately powered to detect differences in
risk and only some of them include risk-defining events
in a composite outcome. In this regard, an advantage of
our approach is that it allows larger sample sizes; hence
more power to detect differences in less common, more
clinically meaningful outcomes.
The potential limitations of our approach arise from
three issues: 1) the fact that the information is obtained
retrospectively from a systematic review and meta-analy-
sis with their inherent caveats; 2) the methodological
issues regarding the pooling of single proportions; and
3) the limitations regarding modeling techniques and
their application to clinical risk-benefit ratio and incre-
mental risk-benefit ratio analysis. With respect to the
first point we considered that an ample sensitivity analy-
sis should establish the robustness of the conclusions. If
the conclusions are not robust, the conduction of a
study using such information should probably be
questioned.
In regard to the second point there are examples of
the application of the proposed pooling techniques [32]
and a major strength of this method is the fact that the
estimates are the result of a comprehensive review and
meta-analysis including all major studies. A potential
problem with the weighting method of Laird and Mos-
t e l l e ri st h a ti tu s e san o r m a lapproximation to propor-
tions which might be problematic if the proportions are
very small because they might not have a normal distri-
bution anymore [33]. In a similar fashion, the statistical
properties of a c2 test to determine heterogeneity might
be adversely affected when proportions are very small. If
this is the case, robustness might be assessed by using
alternate pooling methods or comparing fixed versus
random approaches. Finally, although the modeling
techniques used in this study are not commonly found
in clinical medicine and their application to clinical
decision making was described only very recently hey
are frequent in the economic literature and have been
well validated. Additionally, other concerns have been
recently raised regarding the use of cost-effectiveness
analysis (in our case risk-benefit analysis), namely the
degree of discrepancy between probability-based and
expectation-based methods, as well as non-transitivity in
pair-wise comparisons [34,35]. These problems could
potentially arise in economic studies and their potential
effects on studies using the approach proposed herein
deserves further evaluation. Finally, the performance of
the present approach compared to other methods for
indirect comparisons still remains to be tested.
Conclusions
Herein we demonstrate the application of risk-benefit
analysis to conduct indirect comparisons of competing
interventions using a Bayesian framework and incorpor-
ating the key elements of the decision process (rIsk,
benefit, and willingness-to-accept the risk) and might
p r o v et ob eav a l u a b l ea i di no r d e rt of a c i l i t a t et h e
implementation and practice of evidence-based
medicine.
Appendix 1
Methodology for the calculation of pooled estimates of
proportions
For a collection of k studies, each i individual study giv-
ing a pi proportion
pi = xi

ni (6)
where xi is the number of events and ni the number of
patients in the i
th study; for i=1t ok
n =
k
i=1 ni (7)
and
x =
k
i=1 xi (8)
If homogeneity holds, a ˆ pestimate of the true prob-
ability is
ˆ p =
k
i=1 xi
k
i=1 ni
(9)
with variance
var

ˆ p

=
ˆ p

1 − ˆ p

k
i=1 ni
(10)
The confidence interval can be calculated using the
Wilson score method [36] as follows:

2np + z2 ± z

z2 +4 npq
	
2

n + z2 (11)
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Page 11 of 13where z is the 1 - a/2 point of the standard Normal
distribution, and q =1-p.
If the proportions are not homogeneous then a ran-
dom effects estimator ˆ θR o ft h et r u ep r o p o r t i o nm a yb e
defined as
ˆ θR =
k
i=1 w∗
i pi
k
i=1 w∗
i
(12)
with variance
var

ˆ θR
	
=

k
i=1 w∗
i
−1
(13)
where the weights w∗
i are defined as proposed by Laird
and Mosteller [33]
w∗
i =
1
(¯ p(1 − ¯ p) −ˆ τ2)/ni + ˆ τ2 (14)
where the mean proportion ¯ pfor the k collection of
individual i studies is
¯ p =
K
i=1 pi/k (15)
and where the ˆ τ2 estimate of the variance of the pro-
portions is
ˆ τ2 =
K
i=1

pi − ¯ p
2
k − 1
−
K
i=1 pi

1 − pi

/ni
k
(16)
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